Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-6306 + gemcitabine in advanced solid tumors
NCT05147272Phase 1Terminated
- Sponsor
- Debiopharm
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of lunresertib in solid tumor, sponsored by Debiopharm. Primary endpoints: Treatment-related Adverse Events up to 1.5 years and Dose Limiting Toxicities at 21 days. Started Dec 2021; status: terminated.
02
Drugs
lunresertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05147272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147272.